OBJECTIVE: Cytokeratin 5 (CK5) is an epithelial cell marker implicated in stem and progenitor cell activity in glandular reproductive tissues and endocrine and chemotherapy resistance in estrogen receptor (ER)(+) breast cancer. The goal of this study was to determine the prevalence of CK5 expression in ovarian cancer and the response of CK5(+) cell populations to cisplatin therapy. MATERIALS AND METHODS: Cytokeratin 5 expression was evaluated in 2 ovarian tissue microarrays, representing 137 neoplasms, and 6 ovarian cancer cell lines. Cell lines were treated with IC(50) (half-maximal inhibitory concentration) cisplatin, and the prevalence of CK5(+) cells pretreatment and posttreatment was determined. Proliferation of CK5(+) versus CK5(-) cell populations was determined using 5-bromo-2'-deoxyuridine incorporation. Chemotherapy-induced apoptosis in CK5(+) versus CK5(-) cells was measured using immunohistochemical staining for cleaved caspase-3. RESULTS: Cytokeratin 5 was expressed in 39.3% (42 of 107) of epithelial ovarian cancers with a range of 1% to 80% positive cells. Serous and endometrioid histologic subtypes had the highest percentage of CK5(+) specimens. Cytokeratin 5 expression correlated with ER positivity (38 of 42 CK5(+) tumors were also ER(+)). Cytokeratin 5 was expressed in 5 of 6 overall and 4 of 4 ER(+) epithelial ovarian cancer cell lines ranging from 2.4% to 52.7% positive cells. Cytokeratin 5(+) compared with CK5(-) cells were slower proliferating. The prevalence of CK5(+) cells increased after 48-hour cisplatin treatment in 4 of 5 cell lines tested. Cytokeratin 5(+) ovarian cancer cells compared with CK5(-) ovarian cancer cells were more resistant to cisplatin-induced apoptosis. CONCLUSIONS: Cytokeratin 5 is expressed in a significant proportion of epithelial ovarian cancers and represents a slower proliferating chemoresistant subpopulation that may warrant cotargeting in combination therapy.
OBJECTIVE:Cytokeratin 5 (CK5) is an epithelial cell marker implicated in stem and progenitor cell activity in glandular reproductive tissues and endocrine and chemotherapy resistance in estrogen receptor (ER)(+) breast cancer. The goal of this study was to determine the prevalence of CK5 expression in ovarian cancer and the response of CK5(+) cell populations to cisplatin therapy. MATERIALS AND METHODS:Cytokeratin 5 expression was evaluated in 2 ovarian tissue microarrays, representing 137 neoplasms, and 6 ovarian cancer cell lines. Cell lines were treated with IC(50) (half-maximal inhibitory concentration) cisplatin, and the prevalence of CK5(+) cells pretreatment and posttreatment was determined. Proliferation of CK5(+) versus CK5(-) cell populations was determined using 5-bromo-2'-deoxyuridine incorporation. Chemotherapy-induced apoptosis in CK5(+) versus CK5(-) cells was measured using immunohistochemical staining for cleaved caspase-3. RESULTS:Cytokeratin 5 was expressed in 39.3% (42 of 107) of epithelial ovarian cancers with a range of 1% to 80% positive cells. Serous and endometrioid histologic subtypes had the highest percentage of CK5(+) specimens. Cytokeratin 5 expression correlated with ER positivity (38 of 42 CK5(+) tumors were also ER(+)). Cytokeratin 5 was expressed in 5 of 6 overall and 4 of 4 ER(+) epithelial ovarian cancer cell lines ranging from 2.4% to 52.7% positive cells. Cytokeratin 5(+) compared with CK5(-) cells were slower proliferating. The prevalence of CK5(+) cells increased after 48-hour cisplatin treatment in 4 of 5 cell lines tested. Cytokeratin 5(+) ovarian cancer cells compared with CK5(-) ovarian cancer cells were more resistant to cisplatin-induced apoptosis. CONCLUSIONS:Cytokeratin 5 is expressed in a significant proportion of epithelial ovarian cancers and represents a slower proliferating chemoresistant subpopulation that may warrant cotargeting in combination therapy.
Authors: Adam D Steg; Kerri S Bevis; Ashwini A Katre; Angela Ziebarth; Zachary C Dobbin; Ronald D Alvarez; Kui Zhang; Michael Conner; Charles N Landen Journal: Clin Cancer Res Date: 2011-12-05 Impact factor: 12.531
Authors: Amanda J M O'Donnell; Kenneth G Macleod; David J Burns; John F Smyth; Simon P Langdon Journal: Endocr Relat Cancer Date: 2005-12 Impact factor: 5.678
Authors: Jocelyn M Stewart; Patricia A Shaw; Craig Gedye; Marcus Q Bernardini; Benjamin G Neel; Laurie E Ailles Journal: Proc Natl Acad Sci U S A Date: 2011-03-30 Impact factor: 11.205
Authors: Monique A Spillman; Nicole G Manning; Wendy W Dye; Carol A Sartorius; Miriam D Post; Joshua Chuck Harrell; Britta M Jacobsen; Kathryn B Horwitz Journal: Cancer Res Date: 2010-10-19 Impact factor: 12.701
Authors: Peter Kabos; James M Haughian; Xinshuo Wang; Wendy W Dye; Christina Finlayson; Anthony Elias; Kathryn B Horwitz; Carol A Sartorius Journal: Breast Cancer Res Treat Date: 2010-07-28 Impact factor: 4.872
Authors: Kathryn B Horwitz; Wendy W Dye; Joshua Chuck Harrell; Peter Kabos; Carol A Sartorius Journal: Proc Natl Acad Sci U S A Date: 2008-04-07 Impact factor: 11.205
Authors: Eva Obermayr; Natalia Bednarz-Knoll; Beatrice Orsetti; Heinz-Ulrich Weier; Sandrina Lambrechts; Dan Cacsire Castillo-Tong; Alexander Reinthaller; Elena Ioana Braicu; Sven Mahner; Jalid Sehouli; Ignace Vergote; Charles Theillet; Robert Zeillinger; Burkhard Brandt Journal: Oncotarget Date: 2017-11-16
Authors: Carmela Ricciardelli; Noor A Lokman; Carmen E Pyragius; Miranda P Ween; Anne M Macpherson; Andrew Ruszkiewicz; Peter Hoffmann; Martin K Oehler Journal: Oncotarget Date: 2017-03-14